The MRDR was well-represented at the recent International Myeloma Workshop (IMW) in Boston attended by over 3200 delegates. Prof Andrew Spencer, MRDR Coordinating Principal Investigator, gave an invited presentation on the role of myeloma registries in improving real-world outcomes, and Dr Elizabeth Moore, MRDR research fellow, presented results of My-PROMPT, a pilot randomised controlled trial to test the feasibility of real-time feedback of patient-reported outcomes to clinicians treating patients with multiple myeloma (MM). In a plenary session, Andrew Spencer and MRDR steering committee member Prof Joy Ho represented Australia in an update on clinical trials around the world.
MRDR posters included data on the impact of number of cycles of therapy on outcomes in patients with MM treated with bortezomib induction (A/Prof Peter Mollee), and myeloma in Pacific Islanders in New Zealand (A/Prof Hilary Blacklock). The registry’s presence at this event is a reflection of sites' hard work and shows how the data you provide is being actively used in meaningful research.
The inaugural Asia-Pacific MRDR (APAC MRDR: a sister registry of the MRDR) Investigators’ Meeting was held during IMW. It was well attended by investigators from Korea, China, Hong Kong, Taiwan, Singapore and Australia, who discussed progress with Andrew Spencer and APAC MRDR Project Manager Naomi Aoki.
